Kikuchi N, Onozaki I, Kohno N, Yamaguchi T, Nagao K, Kuriyama T, Kanno H, Kubo S, Tatsumi K, Okita S
Department of Internal Medicine, Chiba Kaihin Municipal Hospital.
Jpn J Antibiot. 1990 Jan;43(1):23-30.
In an open, prospective, multicenter trial the clinical efficacy of imipenem/cilastatin sodium (IPM/CS) for the treatment of 14 cases with aspiration pneumonia was investigated. The mean age was 75.4 years old. Diseases of central nervous system were present in 11 cases, cardiovascular diseases, pulmonary diseases and diabetes mellitus in 2 cases each respectively. Seven cases were community-acquired and another seven were hospital-acquired. Six cases were moderate and 8 cases were severe. Causative organisms were determined in 9 cases (64.3%), multiple causative organisms were isolated in 3 cases. Isolated organisms were Staphylococcus aureus (4), Pseudomonas aeruginosa (3), Klebsiella pneumoniae (3), Escherichia coli (1), Acinetobacter calcoaceticus (1). Detection of anaerobes was not attempted. Clinical effects of IPM/CS were excellent in 3, good in 8, fair in 2, poor in 1, the efficacy rate was thus 78.6%. P. aeruginosa was isolated from 2 out of 3 cases in which therapy with IPM/CS failed. Monotherapy with IPM/CS appears to be highly effective for cases of aspiration pneumonia, but the disease due to IPM-resistant P. aeruginosa is an exception.
在一项开放性、前瞻性、多中心试验中，研究了亚胺培南/西司他丁钠（IPM/CS）治疗14例吸入性肺炎患者的临床疗效。平均年龄为75.4岁。11例存在中枢神经系统疾病，2例分别患有心血管疾病、肺部疾病和糖尿病。7例为社区获得性，另7例为医院获得性。6例为中度，8例为重度。9例（64.3%）确定了病原体，3例分离出多种病原体。分离出的病原体为金黄色葡萄球菌（4例）、铜绿假单胞菌（3例）、肺炎克雷伯菌（3例）、大肠埃希菌（1例）、醋酸钙不动杆菌（1例）。未尝试检测厌氧菌。IPM/CS的临床效果为优3例、良8例、中2例、差1例，有效率为78.6%。在IPM/CS治疗失败的3例患者中，有2例分离出铜绿假单胞菌。IPM/CS单药治疗对吸入性肺炎病例似乎非常有效，但对耐IPM的铜绿假单胞菌引起的疾病是个例外。
